T cell engineering with TCRs is a growing area of cell and gene therapy, with recent FDA approvals. The T-Cure approach involves isolating a high avidity TCR which specifically recognizes an intracellular or cell-surface target in solid tumors. This TCR is then typically introduced into a viral vector that can deliver the TCR into the patients’ own T cells in an ex vivo setting. T-Cure implies a 48-hour cell processing technology, termed turboTCR-T™ for efficient manufacturing. After successful genetic modification of the T cells, TCR-T are re-introduced into the patient, and render effective killing of tumor cells in vivo.